Astellas Pharma Inc.'s Fiscal Year is From April To March - All Figures are in JPY, Billions.
The item "Net-Receivables" stands at 716.36 Billion Japanese Yens as of 09/30/2025, the highest value at least since 03/31/2011, the period currently displayed.
As of the end of Astellas Pharma Inc.'s second quarter, the item "Net Receivables" stands at 716.36 Billion JPY. This represents an increase of 7.10 percent compared to it's value at the end of it's first quarter .
Regarding the One-Year-Change of the series, the current value constitutes an increase of 25.48 percent compared to the value the year prior.
The 1 year change in percent is 25.48.
The 3 year change in percent is 90.84.
The 5 year change in percent is 102.55.
The 10 year change in percent is 103.95.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Net Receivables | 905,699,262,464.00 |
![]() | Johnson & Johnson - Net Receivables | 486,508,953,600.00 |
![]() | AbbVie Inc - Net Receivables | 399,570,305,024.00 |
![]() | Roche Holding AG - Net Receivables | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Net Receivables | 280,205,508,085.11 |